NY-ESO-1 TCR-transduced T cells

NY-ESO-1 TCR-transduced T cells are autologous or allogeneic human T lymphocytes genetically engineered to express a high-affinity, tumor antigen–specific (NY‑ESO‑1) αβT cell receptor (TCR). These modified cells recognize and target the cancer-testis antigen NY‑ESO‑1 presented by HLA-A*02 molecules on tumor cells. The therapy involves isolating patient or donor peripheral blood lymphocytes, transducing them with a retroviral or lentiviral vector encoding an affinity-enhanced NY‑ESO‑1–specific αβTCR (often with silencing of endogenous native human αβTCRs), expanding the modified population ex vivo, and infusing them back into the patient after lymphodepleting chemotherapy. Upon infusion, these engineered cytotoxic CD8+ and helper CD4+ populations can mediate direct lysis of tumor cells expressing NY‑ESO‑1. This approach is under clinical investigation for advanced solid tumors—especially synovial sarcoma—and hematologic malignancies that aberrantly express this highly immunogenic antigen[2][3][4][5][6].

Other names

NY-ESO-1-specific TCR-T cellsNY-ESO1-specific TCR-T cellsNY-ESO 1-specific TCR-T cellsNY-ESO-1-specific redirected T cellsNY-ESO1-specific redirected T cellsNY-ESO 1-specific redirected T cellsNY-ESO-1-specific TCR-engineered T-cell therapyNY-ESO1-specific TCR-engineered T-cell therapyNY-ESO 1-specific TCR-engineered T-cell therapy